

# Pierre Bedossa

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6457146/publications.pdf>

Version: 2024-02-01

219  
papers

29,532  
citations

5268

83  
h-index

5120

166  
g-index

226  
all docs

226  
docs citations

226  
times ranked

25369  
citing authors

#	ARTICLE	IF	CITATIONS
1	Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 713-722.e3.	4.4	9
2	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. <i>JHEP Reports</i> , 2022, 4, 100409.	4.9	20
3	Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery. <i>Hepatology</i> , 2022, 76, 456-468.	7.3	22
4	Clinical Interest of Serum Alpha-2 Macroglobulin, Apolipoprotein A1, and Haptoglobin in Patients with Non-Alcoholic Fatty Liver Disease, with and without Type 2 Diabetes, before or during COVID-19. <i>Biomedicines</i> , 2022, 10, 699.	3.2	7
5	Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e1356-e1366.	3.6	6
6	A new preclinical model of western diet-induced progression of non-alcoholic steatohepatitis to hepatocellular carcinoma. <i>FASEB Journal</i> , 2022, 36, .	0.5	17
7	Fifty years of impact on liver pathology: a history of the Gnomes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 191-200.	2.8	0
8	Identification of a Metabolic, Transcriptomic, and Molecular Signature of Patatin-Like Phospholipase Domain Containing 3-Mediated Acceleration of Steatohepatitis. <i>Hepatology</i> , 2021, 73, 1290-1306.	7.3	37
9	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. <i>Nature</i> , 2021, 592, 450-456.	27.8	649
10	Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort. <i>Journal of Hepatology</i> , 2021, 75, 284-291.	3.7	124
11	Prospective external validation of a new non-invasive test for the diagnosis of non-alcoholic steatohepatitis in patients with type 2 diabetes. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 952-966.	3.7	8
12	Prospective comparison of transient elastography, MRI and serum scores for grading steatosis and detecting non-alcoholic steatohepatitis in bariatric surgery candidates. <i>JHEP Reports</i> , 2021, 3, 100381.	4.9	15
13	Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. <i>Diabetes Care</i> , 2021, 44, 399-406.	8.6	173
14	A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH. <i>New England Journal of Medicine</i> , 2021, 385, 1547-1558.	27.0	284
15	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1170-1178.e6.	4.4	61
16	Cenicriviroc for the treatment of liver fibrosis in adults with nonalcoholic steatohepatitis: AURORA Phase 3 study design. <i>Contemporary Clinical Trials</i> , 2020, 89, 105922.	1.8	92
17	Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2020, 72, 828-838.	3.7	52
18	The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease. <i>Contemporary Clinical Trials</i> , 2020, 98, 106175.	1.8	71

#	ARTICLE	IF	CITATIONS
19	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	205
20	A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 970-985.	8.1	142
21	An Improved qFibrosis Algorithm for Precise Screening and Enrollment into Non-Alcoholic Steatohepatitis (NASH) Clinical Trials. <i>Diagnostics</i> , 2020, 10, 643.	2.6	12
22	The PPAR $\alpha/\delta$ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 9330.	3.3	72
23	Bergamot Polyphenols Improve Dyslipidemia and Pathophysiological Features in a Mouse Model of Non-Alcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2020, 10, 2565.	3.3	63
24	The histone acetyltransferase hMOF promotes vascular invasion in hepatocellular carcinoma. <i>Liver International</i> , 2020, 40, 956-967.	3.9	20
25	FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 362-373.	8.1	411
26	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. <i>Journal of Hepatology</i> , 2020, 73, 252-262.	3.7	170
27	A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>Journal of Hepatology</i> , 2020, 73, 202-209.	3.7	2,171
28	Porto-sinusoidal vascular disease. Vascular liver diseases: Position papers from the francophone network for vascular liver diseases, the French Association for the Study of the Liver (AFLF), and ERN-rare liver. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2020, 44, 447-451.	1.5	5
29	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohort. <i>Journal of Hepatology</i> , 2020, 73, 505-515.	3.7	279
30	Microcirculatory changes in the liver of patients with refractory ascites and their relationship with diabetes and alcohol. <i>European Journal of Gastroenterology and Hepatology</i> , 2020, Publish Ahead of Print, .	1.6	2
31	REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis. <i>Contemporary Clinical Trials</i> , 2019, 84, 105803.	1.8	105
32	Performance of the PRO-C3 collagen neo-epitope biomarker in non-alcoholic fatty liver disease. <i>JHEP Reports</i> , 2019, 1, 188-198.	4.9	86
33	FTY720/fingolimod decreases hepatic steatosis and expression of fatty acid synthase in diet-induced nonalcoholic fatty liver disease in mice. <i>Journal of Lipid Research</i> , 2019, 60, 1311-1322.	4.2	38
34	Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. , 2019, , 245-274.		0
35	Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. <i>Gastroenterology</i> , 2019, 156, 1717-1730.	1.3	777
36	Porto-sinusoidal vascular disease: proposal and description of a novel entity. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 399-411.	8.1	149

#	ARTICLE	IF	CITATIONS
37	ATU-09â€¦Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis. , 2019, , .		0
38	Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet, The, 2019, 394, 2184-2196.	13.7	818
39	Diagnostic Accuracy of Noninvasive Markers of Steatosis, NASH, and Liver Fibrosis in HIV-Monoinfected Individuals at Risk of Nonalcoholic Fatty Liver Disease (NAFLD): Results From the ECHAM Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, e86-e94.	2.1	53
40	Endothelial fatty liver binding protein 4: a new targetable mediator in hepatocellular carcinoma related to metabolic syndrome. Oncogene, 2019, 38, 3033-3046.	5.9	46
41	Data set for the reporting of intrahepatic cholangiocarcinoma, perihilar cholangiocarcinoma and hepatocellular carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR). Histopathology, 2018, 73, 369-385.	2.9	35
42	Influence of Progenitorâ€œDerived Regeneration Markers on Hepatitis C Virusâ€œRelated Cirrhosis Outcome (ANRS CO12 CirVir Cohort). Hepatology, 2018, 68, 1534-1548.	7.3	16
43	Persistence of hepatocellular carcinoma risk in hepatitis C patients with a response to <scp>IFN</scp> and cirrhosis regression. Liver International, 2018, 38, 1459-1467.	3.9	22
44	Diagnosis of nonâ€œalcoholic fatty liver disease/nonâ€œalcoholic steatohepatitis: Why liver biopsy is essential. Liver International, 2018, 38, 64-66.	3.9	57
45	Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science. Hepatology, 2018, 67, 2001-2012.	7.3	125
46	Contribution of virtual biopsy to the screening of microvascular invasion in hepatocellular carcinoma: A pilot study. Liver International, 2018, 38, 687-694.	3.9	17
47	Cellular and Molecular Techniques. , 2018, , 88-110.		2
48	Vascular Disorders. , 2018, , 636-672.		8
49	At similar weight loss, dietary composition determines the degree of glycemic improvement in diet-induced obese C57BL/6 mice. PLoS ONE, 2018, 13, e0200779.	2.5	6
50	Utility and Safety of Liver Biopsy in Patients with Undetermined Liver Blood Test Anomalies after Allogeneic Hematopoietic Stem Cell Transplantation: A Monocentric Retrospective Cohort Study. Biology of Blood and Marrow Transplantation, 2018, 24, 2523-2531.	2.0	19
51	Functional role of ADAMTS5 in adiposity and metabolic health. PLoS ONE, 2018, 13, e0190595.	2.5	12
52	<i>In vitro</i>, <i>in vivo</i> and <i>ex vivo</i> demonstration of the antitumoral role of hypocretin-1/orexin-A and almoxexant in pancreatic ductal adenocarcinoma. Oncotarget, 2018, 9, 6952-6967.	1.8	19
53	Pathology of nonâ€œalcoholic fatty liver disease. Liver International, 2017, 37, 85-89.	3.9	247
54	A prospective study of the utility of plasma biomarkers to diagnose alcoholic hepatitis. Hepatology, 2017, 66, 555-563.	7.3	91

#	ARTICLE	IF	CITATIONS
55	Dietary intervention, but not losartan, completely reverses non-alcoholic steatohepatitis in obese and insulin resistant mice. <i>Lipids in Health and Disease</i> , 2017, 16, 46.	3.0	19
56	Systematic review of bariatric surgery liver biopsies clarifies the natural history of liver disease in patients with severe obesity. <i>Gut</i> , 2017, 66, 1688-1696.	12.1	59
57	The FAT Score, a Fibrosis Score of Adipose Tissue: Predicting Weight-Loss Outcome After Gastric Bypass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 2443-2453.	3.6	62
58	Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis. <i>Clinical Science</i> , 2017, 131, 27-36.	4.3	22
59	Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis. <i>Journal of Hepatology</i> , 2017, 66, 1022-1030.	3.7	734
60	The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease. <i>Scientific Reports</i> , 2017, 7, 17193.	3.3	50
61	Identifying critical steps towards improved access to innovation in cancer care: a European CanCER Organisation position paper. <i>European Journal of Cancer</i> , 2017, 82, 193-202.	2.8	25
62	SAF score and mortality in NAFLD after up to 41 years of follow-up. <i>Scandinavian Journal of Gastroenterology</i> , 2017, 52, 87-91.	1.5	32
63	Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update. <i>Hepatology International</i> , 2017, 11, 1-30.	4.2	178
64	Tumors of the liver. , 2017, , 1272-1298.e7.		1
65	Role of ADAMTS13 in diet-induced liver steatosis. <i>Molecular Medicine Reports</i> , 2017, 16, 1451-1458.	2.4	5
66	Controlled Attenuation Parameter (CAP) with the XL Probe of the Fibroscan®: A Comparative Study with the M Probe and Liver Biopsy. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2569-2577.	2.3	79
67	Serological Tests Do Not Predict Residual Fibrosis in Hepatitis C Cirrhotics with a Sustained Virological Response to Interferon. <i>PLoS ONE</i> , 2016, 11, e0155967.	2.5	23
68	Accumulation of Intrahepatic TNF- $\alpha$ -Producing NKp44+ NK Cells Correlates With Liver Fibrosis and Viral Load in Chronic HCV Infection. <i>Medicine (United States)</i> , 2016, 95, e3678.	1.0	13
69	<sc>ADAMTS</sc>5 deficiency protects against nonalcoholic steatohepatitis in obesity. <i>Liver International</i> , 2016, 36, 1848-1859.	3.9	18
70	AdipoScan: A Novel Transient Elastography-Based Tool Used to Non-Invasively Assess Subcutaneous Adipose Tissue Shear Wave Speed in Obesity. <i>Ultrasound in Medicine and Biology</i> , 2016, 42, 2401-2413.	1.5	11
71	Gly388Arg FGFR4 Polymorphism Is Not Predictive of Everolimus Efficacy in Well-Differentiated Digestive Neuroendocrine Tumors. <i>Neuroendocrinology</i> , 2016, 103, 495-499.	2.5	19
72	Hepatocellular autophagy modulates the unfolded protein response and fasting-induced steatosis in mice. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 311, G599-G609.	3.4	37

#	ARTICLE	IF	CITATIONS
73	MicroRNA-based diagnostic tools for advanced fibrosis and cirrhosis in patients with chronic hepatitis B and C. Scientific Reports, 2016, 6, 34935.	3.3	41
74	Statins, antidiabetic medications and liver histology in patients with diabetes with non-alcoholic fatty liver disease. BMJ Open Gastroenterology, 2016, 3, e000075.	2.7	90
75	A diet-induced animal model of non-alcoholic fatty liver disease and hepatocellular cancer. Journal of Hepatology, 2016, 65, 579-588.	3.7	371
76	Heterozygous Mutations in BMP6 Pro-peptide Lead to Inappropriate Hecpidin Synthesis and Moderate Iron Overload in Humans. Gastroenterology, 2016, 150, 672-683.e4.	1.3	73
77	Acute extrahepatic infectious or inflammatory diseases are a cause of transient mosaic pattern on CT and MR imaging related to sinusoidal dilatation of the liver. European Radiology, 2016, 26, 3094-3101.	4.5	19
78	Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease. Gastroenterology, 2016, 150, 1811-1822.e4.	1.3	93
79	Histological Assessment of NAFLD. Digestive Diseases and Sciences, 2016, 61, 1348-1355.	2.3	44
80	Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease. , 2016, , 223-247.		4
81	Distal intramural and tumor spread in the mesorectum after neoadjuvant radiochemotherapy in rectal cancer: about 124 consecutive patients. Human Pathology, 2016, 52, 164-172.	2.0	14
82	Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor- $\alpha$ and $\beta$ , Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterology, 2016, 150, 1147-1159.e5.	1.3	847
83	Transient excess of liver fat detected by magnetic resonance imaging in women with acute fatty liver of pregnancy. American Journal of Obstetrics and Gynecology, 2016, 214, 127-129.	1.3	22
84	Liver microRNA-21 is overexpressed in non-alcoholic steatohepatitis and contributes to the disease in experimental models by inhibiting PPAR- $\alpha$ expression. Gut, 2016, 65, 1882-1894.	12.1	140
85	Liver Histology and Clinical Trials for Nonalcoholic Steatohepatitis-Perspectives From 2 Pathologists. Gastroenterology, 2015, 149, 1305-1308.	1.3	51
86	Histologic and noninvasive estimates of liver fibrosis. Clinical Liver Disease, 2015, 6, 5-8.	2.1	16
87	Relevance of Adipose Tissue Stiffness Evaluated by Transient Elastography (AdipoScan <sup>®</sup> ) in Morbidly Obese Patients before Bariatric Surgery. Physics Procedia, 2015, 70, 1264-1268.	1.2	7
88	High $\alpha$ -Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis. Histopathology, 2015, 67, 664-676.	2.9	21
89	Somatostatin Receptor Subtype 2 Expression and Somatostatin Receptor Scintigraphy Positivity in Pancreatic Serous Cystadenomas. Pancreas, 2015, 44, 672-674.	1.1	6
90	Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement. PLoS ONE, 2015, 10, e0120299.	2.5	49

#	ARTICLE	IF	CITATIONS
91	Diagnostic performance of controlled attenuation parameter for predicting steatosis grade in chronic hepatitis B. <i>Annals of Hepatology</i> , 2015, 14, 826-836.	1.5	18
92	Diagnosis of Liver Fibrosis: Present and Future. <i>Seminars in Liver Disease</i> , 2015, 35, 166-183.	3.6	49
93	Reversibility of hepatitis <scp>B</scp> virus cirrhosis after therapy: who and why?. <i>Liver International</i> , 2015, 35, 78-81.	3.9	55
94	Patients with chronic hepatitis C without advanced fibrosis and hepatocellular carcinoma: A retrospective clinicalâ€“pathological study. <i>Digestive and Liver Disease</i> , 2015, 47, 296-302.	0.9	2
95	Precore/Core promoter variants to predict significant fibrosis in both <scp>HB</scp>eAg positive and negative chronic hepatitis B. <i>Liver International</i> , 2015, 35, 2082-2089.	3.9	21
96	Performance of PIVKA-II for early hepatocellular carcinoma diagnosis and prediction of microvascular invasion. <i>Journal of Hepatology</i> , 2015, 62, 848-854.	3.7	228
97	Anti-angiogenic effect of metformin in human liver carcinogenesis related to metabolic syndrome. <i>Gut</i> , 2015, 64, 1498-1500.	12.1	12
98	Primary biliary cirrhosis: proposal for a new simple histological scoring system. <i>Liver International</i> , 2015, 35, 652-659.	3.9	22
99	Well-differentiated hepatocellular neoplasm of uncertain malignant potentialâ€“reply. <i>Human Pathology</i> , 2015, 46, 635-636.	2.0	6
100	TRIP: a pathological score for transarterial chemoembolization resistance individualized prediction in hepatocellular carcinoma. <i>Liver International</i> , 2015, 35, 2466-2473.	3.9	24
101	Obesity and Fatty Pancreatic Infiltration Are Risk Factors for Pancreatic Precancerous Lesions (PanIN). <i>Clinical Cancer Research</i> , 2015, 21, 3522-3528.	7.0	165
102	Macrophage activation marker soluble <scp>CD</scp>163 and nonâ€“alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1293-1300.	2.8	53
103	Can pancreatic neuroendocrine tumour biopsy accurately determine pathological characteristics?. <i>Digestive and Liver Disease</i> , 2015, 47, 973-977.	0.9	43
104	Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. <i>Gut</i> , 2015, 64, 673-683.	12.1	64
105	Circulating phospholipid profiling identifies portal contribution to NASH signature in obesity. <i>Journal of Hepatology</i> , 2015, 62, 905-912.	3.7	89
106	Hepatocellular adenoma: Different entities for a single lesion. <i>Annals of Hepatology</i> , 2014, 13, 450-451.	1.5	0
107	Reduction of MicroRNA 122 Expression in <i>IFNL3</i> CT/TT Carriers and during Progression of Fibrosis in Patients with Chronic Hepatitis C. <i>Journal of Virology</i> , 2014, 88, 6394-6402.	3.4	29
108	Pathological prognostic factors in locally advanced rectal carcinoma after neoadjuvant radiochemotherapy: analysis of 113 cases. <i>Histopathology</i> , 2014, 65, 623-630.	2.9	28



#	ARTICLE	IF	CITATIONS
109	Diagnosis of sinusoidal obstruction syndrome by positron emission tomography/computed tomography: Report of two cases treated by defibrotide. <i>Hepatology</i> , 2014, 60, 1789-1791.	7.3	8
110	Progression from cirrhosis to cancer is associated with early ubiquitin post-translational modifications: identification of new biomarkers of cirrhosis at risk of malignancy. <i>Journal of Pathology</i> , 2014, 234, 452-463.	4.5	28
111	Tumoral heterogeneity of hepatic cholangiocarcinomas revealed by MALDI imaging mass spectrometry. <i>Proteomics</i> , 2014, 14, 965-972.	2.2	21
112	AdipoScan - A novel transient elastography based tool to assess subcutaneous adipose tissue shear wave speed in morbidly obese patients. , 2014, , .		2
113	Proteomic screening identifies a YAP-driven signaling network linked to tumor cell proliferation in human schwannomas. <i>Neuro-Oncology</i> , 2014, 16, 1196-1209.	1.2	27
114	Pathology of the liver sinusoids. <i>Histopathology</i> , 2014, 64, 907-920.	2.9	63
115	Association of Adipose Tissue and Liver Fibrosis With Tissue Stiffness in Morbid Obesity: Links With Diabetes and BMI Loss After Gastric Bypass. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, 898-907.	3.6	107
116	Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. <i>Hepatology</i> , 2014, 60, 565-575.	7.3	491
117	In situ proteomic analysis by MALDI imaging identifies ubiquitin and thymosin- $\beta$ 4 as markers of malignant intraductal pancreatic mucinous neoplasms. <i>Pancreatology</i> , 2014, 14, 117-124.	1.1	21
118	Well-differentiated hepatocellular neoplasm of uncertain malignant potential: proposal for a new diagnostic category. <i>Human Pathology</i> , 2014, 45, 658-660.	2.0	58
119	Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1724-1730.e5.	4.4	41
120	Improving performance of liver biopsy in fibrosis assessment. <i>Journal of Hepatology</i> , 2014, 61, 193-195.	3.7	35
121	Hepatocellular adenoma: different entities for a single lesion. <i>Annals of Hepatology</i> , 2014, 13, 450-1.	1.5	0
122	Current histological classification of NAFLD: strength and limitations. <i>Hepatology International</i> , 2013, 7, 765-770.	4.2	45
123	N-Butyl-2-Cyanoacrylate in Gastric Varices: A Cause for Recurrent Sepsis. <i>American Journal of Gastroenterology</i> , 2013, 108, 1937-1938.	0.4	4
124	Cirrhosis Regression and Subclassification. <i>Surgical Pathology Clinics</i> , 2013, 6, 295-309.	1.7	15
125	A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. <i>Journal of Hepatology</i> , 2013, 59, 550-556.	3.7	421
126	The diagnostic accuracy of Fibroscan® for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. <i>Journal of Hepatology</i> , 2013, 59, 251-256.	3.7	131



#	ARTICLE	IF	CITATIONS
127	Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. <i>Journal of Hepatology</i> , 2013, 58, 350-357.	3.7	146
128	Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome. <i>Gut</i> , 2013, 62, 911-919.	12.1	38
129	Imaging mass spectrometry reveals modified forms of histone H4 as new biomarkers of microvascular invasion in hepatocellular carcinomas. <i>Hepatology</i> , 2013, 58, 983-994.	7.3	67
130	A new feature of the MYH9-related syndrome: Chronic transaminase elevation. <i>Hepatology</i> , 2013, 57, 1288-1289.	7.3	5
131	Hypoxia Pathways and Cellular Stress Activate Pancreatic Stellate Cells: Development of an Organotypic Culture Model of Thick Slices of Normal Human Pancreas. <i>PLoS ONE</i> , 2013, 8, e76229.	2.5	20
132	Molecular Profiling of Pancreatic Neuroendocrine Tumors in Sporadic and Von Hippel-Lindau Patients. <i>Clinical Cancer Research</i> , 2012, 18, 2838-2849.	7.0	61
133	The Expression of the Hypoxia Markers CA9 and CXCR4 Is Correlated with Survival in Patients with Neuroendocrine Tumours of the Ileum. <i>Neuroendocrinology</i> , 2012, 95, 214-222.	2.5	16
134	Proteomic Assessment of Markers for Malignancy in the Mucus of Intraductal Papillary Mucinous Neoplasms of the Pancreas. <i>Pancreas</i> , 2012, 41, 169-174.	1.1	18
135	Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma. <i>Pancreas</i> , 2012, 41, 416-421.	1.1	30
136	Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients. <i>Hepatology</i> , 2012, 56, 1751-1759.	7.3	657
137	Direct comparison of diagnostic performance of transient elastography in patients with chronic hepatitis B and chronic hepatitis C. <i>Liver International</i> , 2012, 32, 612-621.	3.9	123
138	Chronic intermittent hypoxia is a major trigger for non-alcoholic fatty liver disease in morbid obese. <i>Journal of Hepatology</i> , 2012, 56, 225-233.	3.7	214
139	IL28B polymorphism is associated with treatment response in patients with genotype 4 chronic hepatitis C. <i>Journal of Hepatology</i> , 2012, 56, 527-532.	3.7	165
140	Structural and inflammatory heterogeneity in subcutaneous adipose tissue: Relation with liver histopathology in morbid obesity. <i>Journal of Hepatology</i> , 2012, 56, 1152-1158.	3.7	75
141	Role of hepatic HCV RNA level on the severity of chronic hepatitis C and response to antiviral therapy. <i>Journal of Clinical Virology</i> , 2012, 53, 43-47.	3.1	3
142	A novel monoclonal antibody for detection of galectin-9 in tissue sections: application to human tissues infected by oncogenic viruses. <i>Infectious Agents and Cancer</i> , 2012, 7, 16.	2.6	13
143	Immunoglobulin G4 Immunostaining of Gastric, Duodenal, or Colonic Biopsies Is Not Helpful for the Diagnosis of Autoimmune Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2012, 10, 91-94.	4.4	66
144	A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. <i>Hepatology</i> , 2012, 56, 532-543.	7.3	354

#	ARTICLE	IF	CITATIONS
145	Tumors of the liver. , 2012, , 1223-1249.e5.		2
146	CMV drives clonal expansion of NKG2C <sup>+</sup> NK cells expressing self-antigen-specific KIRs in chronic hepatitis patients. European Journal of Immunology, 2012, 42, 447-457.	2.9	261
147	Accuracy and disagreement of computed tomography and magnetic resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: Role of biopsy. Hepatology, 2012, 55, 800-806.	7.3	130
148	Performance of Biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in Patients with Severe Obesity: Meta Analysis of Individual Patient Data. PLoS ONE, 2012, 7, e30325.	2.5	117
149	Aberrant Expression of OX1 Receptors for Orexins in Colon Cancers and Liver Metastases: an Openable Gate to Apoptosis. Cancer Research, 2011, 71, 3341-3351.	0.9	79
150	Imaging Mass Spectrometry Provides Fingerprints for Distinguishing Hepatocellular Carcinoma from Cirrhosis. Journal of Proteome Research, 2011, 10, 3755-3765.	3.7	51
151	Changing trends in malignant transformation of hepatocellular adenoma. Gut, 2011, 60, 85-89.	12.1	263
152	Maintenance Therapy With Peginterferon Alfa-2b Does Not Prevent Hepatocellular Carcinoma in Cirrhotic Patients With Chronic Hepatitis C. Gastroenterology, 2011, 140, 1990-1999.	1.3	102
153	Changes in Autophagic Response in Patients with Chronic Hepatitis C Virus Infection. American Journal of Pathology, 2011, 178, 2708-2715.	3.8	58
154	Predictors of tumor response after preoperative chemoradiotherapy for rectal adenocarcinomas. Human Pathology, 2011, 42, 1702-1709.	2.0	28
155	Obliterative portal venopathy: Portal hypertension is not always present at diagnosis. Journal of Hepatology, 2011, 54, 455-461.	3.7	142
156	C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients. Journal of Hepatology, 2011, 55, 660-665.	3.7	98
157	Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). Journal of Hepatology, 2011, 55, 234-235.	3.7	3
158	Fighting the bushfire in HCC trials. Journal of Hepatology, 2011, 55, 276-277.	3.7	20
159	How to assess liver fibrosis in chronic hepatitis C: serum markers or transient elastography vs. liver biopsy?. Liver International, 2011, 31, 13-17.	3.9	56
160	High serum level of alpha-fetoprotein in focal nodular hyperplasia of the liver. Pathology International, 2011, 61, 491-494.	1.3	11
161	Hepatocellular adenomas: Accuracy of magnetic resonance imaging and liver biopsy in subtype classification. Hepatology, 2011, 53, 1182-1191.	7.3	180
162	<i>In vivo</i> hepatic endoplasmic reticulum stress in patients with chronic hepatitis C. Journal of Pathology, 2010, 221, 264-274.	4.5	109

#	ARTICLE	IF	CITATIONS
163	Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2010, 17, 847-856.	3.1	48
164	Fibrosis in Human Adipose Tissue: Composition, Distribution, and Link With Lipid Metabolism and Fat Mass Loss. <i>Diabetes</i> , 2010, 59, 2817-2825.	0.6	511
165	Pathology Analysis Reveals That Dysplastic Pancreatic Ductal Lesions Are Frequent in Patients With Hereditary Pancreatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2010, 8, 206-212.	4.4	43
166	Chemerin Correlates with Markers for Fatty Liver in Morbidly Obese Patients and Strongly Decreases after Weight Loss Induced by Bariatric Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010, 95, 2892-2896.	3.6	225
167	Harmony in liver fibrosis. <i>Journal of Hepatology</i> , 2010, 52, 313-314.	3.7	11
168	Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis. <i>Journal of Hepatology</i> , 2010, 52, 652-657.	3.7	300
169	Diagnostic accuracy of FibroScan and comparison to liver fibrosis biomarkers in chronic viral hepatitis: A multicenter prospective study (the FIBROSTIC study). <i>Journal of Hepatology</i> , 2010, 53, 1013-1021.	3.7	386
170	SCG10 Expression on Activation of Hepatic Stellate Cells Promotes Cell Motility Through Interference with Microtubules. <i>American Journal of Pathology</i> , 2010, 177, 1791-1797.	3.8	11
171	Plasma Proteome to Look for Diagnostic Biomarkers of Early Bacterial Sepsis after Liver Transplantation. <i>Anesthesiology</i> , 2010, 112, 926-935.	2.5	28
172	Does Early Antiretroviral Treatment Prevent Liver Fibrosis in HIV/HCV-Coinfected Patients?. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2009, 50, 234-236.	2.1	13
173	Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis. <i>Hepatology</i> , 2009, 49, 851-859.	7.3	473
174	Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. <i>Hepatology</i> , 2009, 49, 1151-1157.	7.3	414
175	Response to pegylated interferon alfa-2a and ribavirin in chronic hepatitis C genotype 4. <i>Journal of Medical Virology</i> , 2009, 81, 1576-1583.	5.0	47
176	Liver fibrosis: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL). <i>Hepatology International</i> , 2009, 3, 323-333.	4.2	88
177	Heterogeneity of tumor prognostic markers: a reproducibility study applied to liver metastases of pancreatic endocrine tumors. <i>Modern Pathology</i> , 2009, 22, 273-281.	5.5	82
178	Noninvasive assessment of liver fibrosis by stiffness measurement in patients with chronic hepatitis B. <i>Liver International</i> , 2009, 29, 242-247.	3.9	432
179	Assessment of hepatitis C: noninvasive fibrosis markers and/or liver biopsy. <i>Liver International</i> , 2009, 29, 19-22.	3.9	20
180	Liver biopsy: The best, not the gold standard. <i>Journal of Hepatology</i> , 2009, 50, 1-3.	3.7	289

#	ARTICLE	IF	CITATIONS
181	High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: A long-term follow-up study. <i>Journal of Hepatology</i> , 2009, 50, 1084-1092.	3.7	173
182	Liver fibrosis: Screening is not staging. <i>Journal of Hepatology</i> , 2009, 50, 1268-1269.	3.7	4
183	Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: Influence of glycemic status. <i>Journal of Hepatology</i> , 2009, 51, 354-362.	3.7	92
184	Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. <i>Journal of Hepatology</i> , 2009, 51, 93-101.	3.7	83
185	Peginterferon alfa-2b and Ribavirin: Effective in Patients With Hepatitis C Who Failed Interferon alfa/Ribavirin Therapy. <i>Gastroenterology</i> , 2009, 136, 1618-1628.e2.	1.3	225
186	A Single-Center Surgical Experience of 122 Patients With Single and Multiple Hepatocellular Adenomas. <i>Gastroenterology</i> , 2009, 137, 1698-1705.	1.3	347
187	Pancreatic Endocrine Microadenomatosis in Patients With von Hippel-Lindau Disease. <i>American Journal of Surgical Pathology</i> , 2009, 33, 739-748.	3.7	60
188	Insulin resistance impairs sustained virological response rate to pegylated interferon plus ribavirin in HIV+hepatitis C virus-coinfected patients: HOMAVIC-ANRS HCO2 Study. <i>Antiviral Therapy</i> , 2009, 14, 839-845.	1.0	25
189	The Role of Immunohistochemistry in Idiopathic Chronic Intestinal Pseudoobstruction (CIPO). <i>American Journal of Surgical Pathology</i> , 2009, 33, 749-758.	3.7	44
190	Virological response at 4 weeks to predict outcome of hepatitis C treatment with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , 2009, 14, 501-511.	1.0	64
191	Insulin Resistance in Chronic Hepatitis C: Association With Genotypes 1 and 4, Serum HCV RNA Level, and Liver Fibrosis. <i>Gastroenterology</i> , 2008, 134, 416-423.	1.3	475
192	Eradication of Hepatitis C Virus in Patients Successfully Treated for Chronic Hepatitis C. <i>Gastroenterology</i> , 2008, 135, 821-829.	1.3	309
193	Acute Liver Cell Damage in Patients With Anorexia Nervosa: A Possible Role of Starvation-Induced Hepatocyte Autophagy. <i>Gastroenterology</i> , 2008, 135, 840-848.e3.	1.3	165
194	Adipose tissue transcriptomic signature highlights the pathological relevance of extracellular matrix in human obesity. <i>Genome Biology</i> , 2008, 9, R14.	9.6	372
195	Significant gene expression differences in histologically "Normal" liver biopsies: Implications for control tissue. <i>Hepatology</i> , 2008, 48, 953-962.	7.3	25
196	How to Measure the Diagnostic Accuracy of Noninvasive Liver Fibrosis Indices: The Area Under the ROC Curve Revisited. <i>Clinical Chemistry</i> , 2008, 54, 1372-1378.	3.2	119
197	Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 6634-6639.	7.0	84
198	Telangiectatic adenoma: An entity associated with increased body mass index and inflammation. <i>Hepatology</i> , 2007, 46, 140-146.	7.3	157

#	ARTICLE	IF	CITATIONS
199	Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: A prospective study. <i>Hepatology</i> , 2007, 46, 380-387.	7.3	128
200	Identification of Potential Therapeutic Targets by Gene-Expression Profiling in Pancreatic Endocrine Tumors. <i>Gastroenterology</i> , 2006, 131, 1597-1610.	1.3	72
201	Direct and indirect evidence for the reversibility of cirrhosis. <i>Human Pathology</i> , 2006, 37, 1519-1526.	2.0	95
202	Global proteomic analysis of microdissected cirrhotic nodules reveals significant biomarkers associated with clonal expansion. <i>Laboratory Investigation</i> , 2006, 86, 951-958.	3.7	17
203	Hepatic steatosis in HIV/HCV coinfecting patients: analysis of risk factors. <i>Aids</i> , 2006, 20, 525-531.	2.2	77
204	Increased Infiltration of Macrophages in Omental Adipose Tissue Is Associated With Marked Hepatic Lesions in Morbid Human Obesity. <i>Diabetes</i> , 2006, 55, 1554-1561.	0.6	513
205	Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. <i>Virology</i> , 2005, 332, 130-144.	2.4	145
206	Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases. <i>Hepatology</i> , 2005, 41, 40-47.	7.3	204
207	Sources of variability in histological scoring of chronic viral hepatitis. <i>Hepatology</i> , 2005, 41, 257-264.	7.3	471
208	Liver Gene Expression Signature of Mild Fibrosis in Patients With Chronic Hepatitis C. <i>Gastroenterology</i> , 2005, 129, 2064-2075.	1.3	161
209	Telangiectatic focal nodular hyperplasia: a variant of hepatocellular adenoma. <i>Gastroenterology</i> , 2004, 126, 1323-1329.	1.3	205
210	Reversibility of hepatitis C virus-related cirrhosis. <i>Human Pathology</i> , 2004, 35, 107-112.	2.0	128
211	Sampling variability of liver fibrosis in chronic hepatitis C. <i>Hepatology</i> , 2003, 38, 1449-1457.	7.3	1,690
212	Liver extracellular matrix in health and disease. <i>Journal of Pathology</i> , 2003, 200, 504-515.	4.5	224
213	A comparison of fibrosis progression in chronic liver diseases. <i>Journal of Hepatology</i> , 2003, 38, 257-265.	3.7	401
214	Replicative senescence in normal liver, chronic hepatitis C, and hepatocellular carcinomas. <i>Human Pathology</i> , 2001, 32, 327-332.	2.0	268
215	High glucose and hyperinsulinemia stimulate connective tissue growth factor expression: A potential mechanism involved in progression to fibrosis in nonalcoholic steatohepatitis. <i>Hepatology</i> , 2001, 34, 738-744.	7.3	461
216	Natural history of HCV infection. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2000, 14, 211-228.	2.4	86

#	ARTICLE	IF	CITATIONS
217	Impact of Interferon Alfa-2b and Ribavirin on Progression of Liver Fibrosis in Patients With Chronic Hepatitis C. Hepatology, 2000, 32, 1131-1137.	7.3	257
218	Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Journal of Hepatology, 1998, 28, 439-446.	3.7	189
219	Non-Invasive Markers of Liver Fibrosis: Useful or Useless?. , 0, , 1-5.		0